StockData
Scinai Immunotherapeutics Ltd. logo

Scinai Immunotherapeutics Ltd. (SCNI) shareholders

SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 6/30
$0.37−0.03 (-7.82%)

Close on Nov 17, 2026Market cap $1.29MP/E –Yield –

Ownership

Who owns Scinai Immunotherapeutics's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Lck Jnk 1 LLC317,3666.33%13G (passive) amendmentApr 27, 2026
Mark Angelo
Joint filing with YA II PN, Ltd. (9.90%), YA Global Investments II (U.S.), LP (9.90%) and 5 more
93,2749.90%13G (passive)Mar 24, 2025
Stone Daniel E.
Joint filing with RK Stone Miami, LLC (7.12%)
09.90%13G (passive) amendmentJun 4, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Amir ReichmanChief Executive Officer, Director711,637,6005.13%Jun 18, 2026
Elad MarkChief Operating Officer160,355,0161.16%Mar 26, 2026
Mark GermainDirector120,000,0000.86%Jun 18, 2026
Yael MargolinDirector66,8000.00%Mar 18, 2026
Uri Ben-OrDirector33,329,0040.24%Mar 18, 2026
Samuel J. MoedDirector––Mar 18, 2026
Adi RavivDirector66,8000.00%Mar 18, 2026
Jay GreenDirector––Mar 18, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Amir Reichman
Chief Executive Officer, Director
Jun 16, 2026Award+400,000,000––711,637,600
Mark Germain
Director
Jun 16, 2026Award+120,000,000––120,000,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-80.5%
From 0M shares
Short volume, 20 days
44.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Scinai Immunotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 271,050 shares on Sep 15, 2026 over the last 90 days.

See a number that looks wrong?